BioSpace News Archive

Patients Treated with LYNPARZA and Bevacizumab Lived Without Disease Progression or Death for a Median of 37.2 Months vs. 17.7 Months with Bevacizumab Alone Following Response to Platinum-Based Chemotherapy

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.

Evolent Health (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will host its annual Investor and Analyst Day on Tuesday, September 29, 2020 , from 10:00 a.m. ET to 12:30 p.m. ET . This year’s event will be held virtually. To register for

Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis. “We are pleased to complete the transaction with Forbius and add their TGF-beta program to

BioLife Sciences Inc. (OTC Markets: BLFE) announced today that it has entered into an agreement with BeMotion Inc. to become a licensed distributor of the company’s innovative technology products. Under the terms of the agreement, BioLife Sciences will gain the right to distribute products by BeMotion which include non-contact human temperature screening technology, ultraviolet sterilization, and touchless vending/marketp

TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 90% of the planned 500 patients enrolled Fast-Track designation granted by U.S. FDA Interim superiority analysis expected in Q1 2021 ; final analysis in 2H of 2021 NOPHO-sponsored Phase 2 trial in second-line acute lymphoblastic leukemia: Completed patient enrollment : 55 patients enrolled Encouraging interim results: target level and duration of asparaginase activity reached

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, is a presenting sponsor and exhibitor at The Virtual MedTech Conference taking place September 8 – October 23, 2020. The Solutions Showcase presentation ‘Data Driven Studies: Unified eClinical Platforms to Run Your Clinical Trials’ is available on-demand as of today, September 21, 2020, at 12:00 AM EDT. The session features Andrew Schachter, Axiom’s Fou

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the commencement of a proposed underwritten public offering of 5,500,000 shares of its common shares. Certain existing shareholders expect t

Amwell®, a national telehealth leader, today announced the closing of its upsized initial public offering of 47,405,555 shares of its Class A common stock at an initial offering price of $18.00 per share,

Forbion, a leading European life sciences venture capital firm, notes that its portfolio company Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY).